BRNS
7:30 AM
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending
barinthusbio.com